<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 31 11:50:25 UTC 2026 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://galectintherapeutics.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:galt="http://galectintherapeutics.com/20251231" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20251231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20251231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20251231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="galt-20251231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheet" id="galt_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedBalanceSheet_Parentheticals" id="galt_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedIncomeStatement" id="galt_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ShareholdersEquityType2or3" id="galt_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConsolidatedCashFlow" id="galt_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/NatureofBusinessBasisofPresentationLiquidityandGoingConcern" id="galt_r_NatureofBusinessBasisofPresentationLiquidityandGoingConcern">
        <link:definition>995306 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryofSignificantAccountingPolicies" id="galt_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyandEquipment" id="galt_r_PropertyandEquipment">
        <link:definition>995308 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpenses" id="galt_r_AccruedExpenses">
        <link:definition>995309 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedParty" id="galt_r_ConvertibleNotesPayableRelatedParty">
        <link:definition>995310 - Disclosure - Convertible Notes Payable &#8211; Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstruments" id="galt_r_FairValueofFinancialInstruments">
        <link:definition>995311 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquity" id="galt_r_StockholdersEquity">
        <link:definition>995312 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Warrants" id="galt_r_Warrants">
        <link:definition>995313 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensation" id="galt_r_StockBasedCompensation">
        <link:definition>995314 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineofCreditRelatedPartyandSupplementalLinesofCreditRelatedParty" id="galt_r_ConvertibleLineofCreditRelatedPartyandSupplementalLinesofCreditRelatedParty">
        <link:definition>995315 - Disclosure - Convertible Line of Credit &#8211; Related Party and Supplemental Lines of Credit &#8211; Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShare" id="galt_r_LossPerShare">
        <link:definition>995316 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsandContingencies" id="galt_r_CommitmentsandContingencies">
        <link:definition>995317 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLLC" id="galt_r_GalectinSciencesLLC">
        <link:definition>995318 - Disclosure - Galectin Sciences LLC</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxes" id="galt_r_IncomeTaxes">
        <link:definition>995319 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/Segments" id="galt_r_Segments">
        <link:definition>995320 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccountingPoliciesByPolicy" id="galt_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyandEquipmentTables" id="galt_r_PropertyandEquipmentTables">
        <link:definition>996001 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesTables" id="galt_r_AccruedExpensesTables">
        <link:definition>996002 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstrumentsTables" id="galt_r_FairValueofFinancialInstrumentsTables">
        <link:definition>996003 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsTables" id="galt_r_WarrantsTables">
        <link:definition>996004 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensationTables" id="galt_r_StockBasedCompensationTables">
        <link:definition>996005 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/LossPerShareTables" id="galt_r_LossPerShareTables">
        <link:definition>996006 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsandContingenciesTables" id="galt_r_CommitmentsandContingenciesTables">
        <link:definition>996007 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxesTables" id="galt_r_IncomeTaxesTables">
        <link:definition>996008 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsTables" id="galt_r_SegmentsTables">
        <link:definition>996009 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/NatureofBusinessBasisofPresentationLiquidityandGoingConcernDetails" id="galt_r_NatureofBusinessBasisofPresentationLiquidityandGoingConcernDetails">
        <link:definition>996010 - Disclosure - Nature of Business, Basis of Presentation, Liquidity, and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" id="galt_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996011 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PropertyandEquipmentTable" id="galt_r_PropertyandEquipmentTable">
        <link:definition>996012 - Disclosure - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AccruedExpensesTable" id="galt_r_AccruedExpensesTable">
        <link:definition>996013 - Disclosure - Accrued Expenses - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleNotesPayableRelatedPartyDetails" id="galt_r_ConvertibleNotesPayableRelatedPartyDetails">
        <link:definition>996014 - Disclosure - Convertible Notes Payable &#8211; Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/FairValueofFinancialInstrumentsDetails" id="galt_r_FairValueofFinancialInstrumentsDetails">
        <link:definition>996015 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AssetsandLiabilitiesMeasuredandRecordedatFairValueonRecurringBasisTable" id="galt_r_AssetsandLiabilitiesMeasuredandRecordedatFairValueonRecurringBasisTable">
        <link:definition>996016 - Disclosure - Fair Value of Financial Instruments - Assets and Liabilities Measured and Recorded at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AprilNoteKeyAssumptionsTable" id="galt_r_AprilNoteKeyAssumptionsTable">
        <link:definition>996017 - Disclosure - Fair Value of Financial Instruments - April Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofAprilNoteDerivativeLiabilityTable" id="galt_r_RollForwardofAprilNoteDerivativeLiabilityTable">
        <link:definition>996018 - Disclosure - Fair Value of Financial Instruments - Roll Forward of April Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SeptemberNoteKeyAssumptionsTable" id="galt_r_SeptemberNoteKeyAssumptionsTable">
        <link:definition>996019 - Disclosure - Fair Value of Financial Instruments - September Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofSeptemberNoteDerivativeLiabilityTable" id="galt_r_RollForwardofSeptemberNoteDerivativeLiabilityTable">
        <link:definition>996020 - Disclosure - Fair Value of Financial Instruments - Roll Forward of September Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/DecemberNoteKeyAssumptionsTable" id="galt_r_DecemberNoteKeyAssumptionsTable">
        <link:definition>996021 - Disclosure - Fair Value of Financial Instruments - December Note, Key Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/RollForwardofDecemberNoteDerivativeLiabilityTable" id="galt_r_RollForwardofDecemberNoteDerivativeLiabilityTable">
        <link:definition>996022 - Disclosure - Fair Value of Financial Instruments - Roll Forward of December Note Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockholdersEquityDetails" id="galt_r_StockholdersEquityDetails">
        <link:definition>996023 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantsDetails" id="galt_r_WarrantsDetails">
        <link:definition>996024 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WarrantActivityTable" id="galt_r_WarrantActivityTable">
        <link:definition>996025 - Disclosure - Warrants - Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/OutstandingWarrantsIssuedinConnectionwithEquityandDebtFinancingsandConsultantsTable" id="galt_r_OutstandingWarrantsIssuedinConnectionwithEquityandDebtFinancingsandConsultantsTable">
        <link:definition>996026 - Disclosure - Warrants - Outstanding Warrants Issued in Connection with Equity and Debt Financings and Consultants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockBasedCompensationDetails" id="galt_r_StockBasedCompensationDetails">
        <link:definition>996027 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ComponentsofStockBasedCompensationExpenseTable" id="galt_r_ComponentsofStockBasedCompensationExpenseTable">
        <link:definition>996028 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/WeightedAverageAssumptionsUsedtoDetermineFairValueofOptionsGrantedTable" id="galt_r_WeightedAverageAssumptionsUsedtoDetermineFairValueofOptionsGrantedTable">
        <link:definition>996029 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/StockOptionActivityTable" id="galt_r_StockOptionActivityTable">
        <link:definition>996030 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/OutstandingandExercisableOptionsunderStockBasedCompensationPlansTable" id="galt_r_OutstandingandExercisableOptionsunderStockBasedCompensationPlansTable">
        <link:definition>996031 - Disclosure - Stock-Based Compensation - Outstanding and Exercisable Options under Stock Based Compensation Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ConvertibleLineofCreditRelatedPartyandSupplementalLinesofCreditRelatedPartyDetails" id="galt_r_ConvertibleLineofCreditRelatedPartyandSupplementalLinesofCreditRelatedPartyDetails">
        <link:definition>996032 - Disclosure - Convertible Line of Credit &#8211; Related Party and Supplemental Lines of Credit &#8211; Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareTable" id="galt_r_AntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareTable">
        <link:definition>996033 - Disclosure - Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/CommitmentsandContingenciesDetails" id="galt_r_CommitmentsandContingenciesDetails">
        <link:definition>996034 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/MaturityofOperatingLeaseTable" id="galt_r_MaturityofOperatingLeaseTable">
        <link:definition>996035 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/GalectinSciencesLLCDetails" id="galt_r_GalectinSciencesLLCDetails">
        <link:definition>996036 - Disclosure - Galectin Sciences LLC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/IncomeTaxesDetails" id="galt_r_IncomeTaxesDetails">
        <link:definition>996037 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/ComponentsofNetDeferredTaxAssetsTable" id="galt_r_ComponentsofNetDeferredTaxAssetsTable">
        <link:definition>996038 - Disclosure - Income Taxes - Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/PrimaryFactorsAffectingIncomeTaxRatesTable" id="galt_r_PrimaryFactorsAffectingIncomeTaxRatesTable">
        <link:definition>996039 - Disclosure - Income Taxes - Primary Factors Affecting Income Tax Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SegmentsDetails" id="galt_r_SegmentsDetails">
        <link:definition>996040 - Disclosure - Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/SignificantExpenseandAssetCategoriesTable" id="galt_r_SignificantExpenseandAssetCategoriesTable">
        <link:definition>996041 - Disclosure - Segments - Significant Expense and Asset Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://galectintherapeutics.com/role/AdditionalCalculations" id="galt_r_AdditionalCalculations">
        <link:definition>996042 - Disclosure - AdditionalCalculations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-sub-2025.xsd"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_UnlabeledAbstract0"/>
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyCurrent"/>
  <xs:element name="ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertibleNotePayableAndAccruedInterestNetOfDebtDiscountRelatedPartyNonCurrent"/>
  <xs:element name="BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_BorrowingAndAccruedInterestUnderLineOfCreditNetOfDebtDiscountRelatedPartyNoncurrent"/>
  <xs:element name="UndesignatedCapitalStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockValue"/>
  <xs:element name="UndesignatedCapitalStockParValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockParValue"/>
  <xs:element name="UndesignatedCapitalStockSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockSharesAuthorized"/>
  <xs:element name="UndesignatedCapitalStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_UndesignatedCapitalStockSharesDesignated"/>
  <xs:element name="ConvertiblePreferredStockDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertiblePreferredStockDividends"/>
  <xs:element name="ConvertiblePreferredStockDividendsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertiblePreferredStockDividendsShares"/>
  <xs:element name="TemporaryEquityDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_TemporaryEquityDividends"/>
  <xs:element name="TemporaryEquityDividendsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_TemporaryEquityDividendsShares"/>
  <xs:element name="StockIssuedDuringPeriodValueWarrantExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodValueWarrantExercise"/>
  <xs:element name="StockIssuedDuringPeriodSharesWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodSharesWarrantExercise"/>
  <xs:element name="StockIssuedDuringPeriodValueStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodValueStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_StockIssuedDuringPeriodSharesStockBasedCompensationExpenseNetOfSharesForfeitedToCoverTaxWithholding"/>
  <xs:element name="CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_CommonStockPurchaseWarrantsIssuedInConnectionWithRelatedPartyLineOfCredit"/>
  <xs:element name="CommonStockWarrantsDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_CommonStockWarrantsDisclosureTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
  <xs:element name="SecurityDepositPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SecurityDepositPolicyTextBlock"/>
  <xs:element name="AccruedExpensePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_AccruedExpensePolicyTextBlock"/>
  <xs:element name="ShareBasedPaymentArrangementWarrantsActivityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedPaymentArrangementWarrantsActivityTableTextBlock"/>
  <xs:element name="AccruedResearchAndDevelopmentCostsAndOtherCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_AccruedResearchAndDevelopmentCostsAndOtherCurrent"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExpired"/>
  <xs:element name="WarrantIssueDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantIssueDate"/>
  <xs:element name="FairValueAdjustmentOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_FairValueAdjustmentOfWarrant"/>
  <xs:element name="QuarterlyInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_QuarterlyInterestRate"/>
  <xs:element name="AnnualInterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_AnnualInterestRate"/>
  <xs:element name="NumberOfLoansClosing" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfLoansClosing"/>
  <xs:element name="NumberOfPromissoryNotesEvidencedByLoansAgreement" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfPromissoryNotesEvidencedByLoansAgreement"/>
  <xs:element name="NumberOfPromissoryNotesExecuted" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfPromissoryNotesExecuted"/>
  <xs:element name="AggregateOfferingPrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_AggregateOfferingPrice"/>
  <xs:element name="CommissionRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_CommissionRate"/>
  <xs:element name="PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_PercentageOfWeightedAverageStockPriceForDividendsPriorToPaymentDate"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfConsecutiveTradingDays"/>
  <xs:element name="ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_ProceedsFromIssuanceOfPreferredStockNetOfIssuanceCosts"/>
  <xs:element name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfWarrantOrRightIssued"/>
  <xs:element name="EquityIssuancePerShareAmount" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_EquityIssuancePerShareAmount"/>
  <xs:element name="CommonSharesIssuableUponConversionOfConvertibleStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_CommonSharesIssuableUponConversionOfConvertibleStock"/>
  <xs:element name="DividendAsPercentageOfNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DividendAsPercentageOfNetSales"/>
  <xs:element name="PostConversionDividendRightsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_PostConversionDividendRightsIssued"/>
  <xs:element name="ClosingDaysAfterConversionRights" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ClosingDaysAfterConversionRights"/>
  <xs:element name="PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_PostConversionRedemptionRightReturnOnInvestmentMultiplierAmount"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodOne" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodOne"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodTwo" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodTwo"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodThree" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodThree"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodFour" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodFour"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodFive" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodFive"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodSix" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodSix"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodSeven" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodSeven"/>
  <xs:element name="ReturnOnInvestmentsPercentagePeriodEight" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ReturnOnInvestmentsPercentagePeriodEight"/>
  <xs:element name="ConvertiblePreferredStockNumberOfVotingRights" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ConvertiblePreferredStockNumberOfVotingRights"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermOfAward"/>
  <xs:element name="VestingPercentageOfRestrictedStockUnits" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_VestingPercentageOfRestrictedStockUnits"/>
  <xs:element name="NumberOfDirectors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfDirectors"/>
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInCashPercent"/>
  <xs:element name="DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementWithIndividualCashAwardGrantedPaidInDeferredStockUnitsPercent"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodOne"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodTwo"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodThree"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFour"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodFive"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSix"/>
  <xs:element name="DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredCompensationArrangementPercentageOfDeferredShareUnitsShallBeIssuedPeriodSeven"/>
  <xs:element name="ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfAdditionalWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
  <xs:element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPercentageEqualToCommonStock"/>
  <xs:element name="IssuanceOfWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_IssuanceOfWarrantsValue"/>
  <xs:element name="DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_DebtInstrumentAccruedInterest"/>
  <xs:element name="NumberOfOperatingLeases" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_NumberOfOperatingLeases"/>
  <xs:element name="FreeRentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_FreeRentPeriod"/>
  <xs:element name="ContractCancelationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContractCancelationNoticePeriod"/>
  <xs:element name="CapitalContributionExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="galt_CapitalContributionExpense"/>
  <xs:element name="NonCashChargeForResearchAndDevelopmentInProcess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="galt_NonCashChargeForResearchAndDevelopmentInProcess"/>
  <xs:element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_OperatingLossCarryforwardsExpirationYear"/>
  <xs:element name="FederalAndStateResearchAndDevelopmentCreditsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_FederalAndStateResearchAndDevelopmentCreditsExpirationYear"/>
  <xs:element name="DeferredTaxAssetsValuationAllowancePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="galt_DeferredTaxAssetsValuationAllowancePercentage"/>
  <xs:element name="AdditionalSupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_AdditionalSupplementalLineOfCreditMember"/>
  <xs:element name="April302025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_April302025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="AprilConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_AprilConvertiblePromissoryNoteMember"/>
  <xs:element name="BusinessOperatingSegmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_BusinessOperatingSegmentMember"/>
  <xs:element name="ComputerAndOfficeEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ComputerAndOfficeEquipmentMember"/>
  <xs:element name="ContingentInterestAprilNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestAprilNoteMember"/>
  <xs:element name="ContingentInterestDecemberNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestDecemberNoteMember"/>
  <xs:element name="ContingentInterestSeptemberNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ContingentInterestSeptemberNoteMember"/>
  <xs:element name="December2022PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2022PromissoryNoteMember"/>
  <xs:element name="December2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2023PromissoryNoteMember"/>
  <xs:element name="December2025SupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December2025SupplementalLineOfCreditMember"/>
  <xs:element name="December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December292023WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="December312025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_December312025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="DecemberConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DecemberConvertiblePromissoryNoteMember"/>
  <xs:element name="DividendPaymentScenarioOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DividendPaymentScenarioOneMember"/>
  <xs:element name="DividendPaymentScenarioTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DividendPaymentScenarioTwoMember"/>
  <xs:element name="EquityIncentivePlan2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_EquityIncentivePlan2019Member"/>
  <xs:element name="ExercisePriceRangeFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExercisePriceRangeFourMember"/>
  <xs:element name="ExercisePriceRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExercisePriceRangeOneMember"/>
  <xs:element name="ExercisePriceRangeThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExercisePriceRangeThreeMember"/>
  <xs:element name="ExercisePriceRangeTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExercisePriceRangeTwoMember"/>
  <xs:element name="ExpiringAsAResultOf2017TaxActMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExpiringAsAResultOf2017TaxActMember"/>
  <xs:element name="ExpiringThrough2037Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_ExpiringThrough2037Member"/>
  <xs:element name="FirstClosingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_FirstClosingMember"/>
  <xs:element name="GalectinSciencesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_GalectinSciencesLLCMember"/>
  <xs:element name="IncentiveCompensationPlanTwoThousandNineMemberMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_IncentiveCompensationPlanTwoThousandNineMemberMember"/>
  <xs:element name="July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_July222022WarrantsIssuedInConnectionWithRelatedPartyLineOfCreditMember"/>
  <xs:element name="June2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June2023PromissoryNoteMember"/>
  <xs:element name="June2024PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June2024PromissoryNoteMember"/>
  <xs:element name="June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June282024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="June302025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_June302025WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="March2023PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March2023PromissoryNoteMember"/>
  <xs:element name="March2025SupplementalCreditAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March2025SupplementalCreditAgreementMember"/>
  <xs:element name="March24PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March24PromissoryNoteMember"/>
  <xs:element name="March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_March292024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_MayTwentyThreeTwentyNinteenRightsOfferingWarrantsMember"/>
  <xs:element name="SBHSciencesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SBHSciencesIncMember"/>
  <xs:element name="SecondClosingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SecondClosingMember"/>
  <xs:element name="September2024PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_September2024PromissoryNoteMember"/>
  <xs:element name="September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_September302024WarrantsIssuedForDrawOnRelatedPartyLineOfCreditMember"/>
  <xs:element name="SeptemberConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeptemberConvertiblePromissoryNoteMember"/>
  <xs:element name="SeriesBOneConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeriesBOneConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBThreeConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeriesBThreeConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBTwoConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SeriesBTwoConvertiblePreferredStockMember"/>
  <xs:element name="SupplementalLineOfCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_SupplementalLineOfCreditMember"/>
  <xs:element name="TwoThousandTwentyMarketAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_TwoThousandTwentyMarketAgreementMember"/>
  <xs:element name="WarrantEightMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantEightMember"/>
  <xs:element name="WarrantFiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantFiveMember"/>
  <xs:element name="WarrantFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantFourMember"/>
  <xs:element name="WarrantNineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantNineMember"/>
  <xs:element name="WarrantOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantOneMember"/>
  <xs:element name="WarrantSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantSevenMember"/>
  <xs:element name="WarrantSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantSixMember"/>
  <xs:element name="WarrantThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantThreeMember"/>
  <xs:element name="WarrantTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantTwoMember"/>
  <xs:element name="WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_WarrantsAbstract"/>
<!-- [WMV6][jay70WYrHtfEMPT/bgY68vtbeNStRSrUZMGMx8830VPeecnbU01ysJ8ipX59z6GxSHWn3JKCfOEsVFmfsbw8SrV3yxyhyZKLeNSvbGJgQx1JLuDnZIm+5zmghunorhso3h6hwShawDHSmSqPhXxrpbMMNL2Hh7Gv2byN28wfAifTAZ9nJe+DtFtlnSaI9YcAG5vX9aE1+nkNUN12a399wPXKGYxD3A7cueximWChwXWXRq41IRfjt6b+LHNzD/lSucadTw3c3+iOTie5XdtXczsP094C0vLS2eoidFYMkqsDJDPNi+iUhm5kBLp7j4FKQRfpQuSOjnz06i0OsqVlNMQ7MDS6p/3tvgGNbEqWZfI0] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="galt_DocumentAndEntityInformationAbstract"/>
</xs:schema>
